Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,467 public trials 2,848 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Active, not recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

NCT04576156

Conditions
Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, +6 more
Locations
  • University of California-San Diego/Moores UCSD Cancer Center La Jolla, California, United States
  • UCLA David Geffen School of Medicine Los Angeles, California, United States
  • Smilow Cancer Center at YNHH New Haven, Connecticut, United States
  • BRCR Medical Center Inc Plantation, Florida, United States
View all 144 locations
View Trial Details
Active, not recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

NCT06169215

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UCI Health Laguna Hills Laguna Hills, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 27 locations
View Trial Details
Active, not recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +16 more
Locations
  • The University of Arizona Cancer Center - North Campus /ID# 242219 Tucson, Arizona, United States
  • Yale University School of Medicine /ID# 242089 New Haven, Connecticut, United States
  • Christiana Care Health Service /ID# 242301 Newark, Delaware, United States
  • Tampa General Hospital /ID# 246748 Tampa, Florida, United States
View all 76 locations
View Trial Details
Active, not recruiting

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT03399799

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • City of Hope Duarte, California, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Mount Sinai Medical Center New York, United States
View all 13 locations
View Trial Details
Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +7 more
Locations
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • University of Colorado Denver, Children's Hospital Aurora, Colorado, United States
  • Tulane University Health Sciences Center New Orleans, Louisiana, United States
View all 32 locations
View Trial Details
Active, not recruiting

Lenalidomide Maintenance in Plasma Cell Myeloma

NCT02538198

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Memorial Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States
  • Memorial Sloan Kettering Westchester Harrison, New York, United States
View Trial Details
Active, not recruiting

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

NCT02935361

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myelomonocytic Leukemia, +14 more
Locations
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
  • Fox Chase Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details

Related conditions